Is Risk Stratification for Bleeding and Ischemic Events Still Useful When De-Escalating to Ticagrelor Monotherapy?
- PMID: 37587581
- DOI: 10.1016/j.jacc.2023.06.010
Is Risk Stratification for Bleeding and Ischemic Events Still Useful When De-Escalating to Ticagrelor Monotherapy?
Keywords: aspirin; bleeding; dual antiplatelet therapy; monotherapy; risk; ticagrelor.
Conflict of interest statement
Funding Support and Author Disclosures Dr Parikh has served as a consultant for Medtronic, Inc; and has received institutional research support from Edwards Lifesciences and Abbott. Dr Palmerini has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions.J Am Coll Cardiol. 2023 Aug 22;82(8):687-700. doi: 10.1016/j.jacc.2023.05.062. J Am Coll Cardiol. 2023. PMID: 37587580 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical